CVRx Securities Fraud Investigation

Block & Leviton is investigating CVRx, Inc. for potential securities law violations. The investigation focuses on whether CVRx and certain executives misrepresented or failed to disclose material information about sales execution, growth, and revenue outlook. On August 6, 2026, CVRx cut its full-year revenue guidance to $58-60 million from $63-67 million, citing rapid sales-force hiring that strained onboarding and training, elevated turnover, slower productivity ramp for new territory managers, and negative implant growth in nearly half of its regions. The company also cited a prolonged reimbursement challenge with a major Medicare Advantage payer and disclosed it had received a civil investigative demand from the Department of Justice in May 2026 regarding sales and marketing practices. Block & Leviton is seeking to recover losses for investors who purchased CVRx common stock.